WO2004111090A3 - Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation - Google Patents

Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation Download PDF

Info

Publication number
WO2004111090A3
WO2004111090A3 PCT/FR2004/001435 FR2004001435W WO2004111090A3 WO 2004111090 A3 WO2004111090 A3 WO 2004111090A3 FR 2004001435 W FR2004001435 W FR 2004001435W WO 2004111090 A3 WO2004111090 A3 WO 2004111090A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
molecules
segment
therapeutic
therapeutic compounds
Prior art date
Application number
PCT/FR2004/001435
Other languages
English (en)
Other versions
WO2004111090A2 (fr
Inventor
Francoise Russo-Marie
Alain Samson
Original Assignee
Bionexis
Francoise Russo-Marie
Alain Samson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionexis, Francoise Russo-Marie, Alain Samson filed Critical Bionexis
Priority to EP04767301A priority Critical patent/EP1631592A2/fr
Priority to US10/560,025 priority patent/US20060154854A1/en
Priority to CA002528186A priority patent/CA2528186A1/fr
Publication of WO2004111090A2 publication Critical patent/WO2004111090A2/fr
Publication of WO2004111090A3 publication Critical patent/WO2004111090A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention se rapporte à des molécules chimères permettant le ciblage et la libération de composés thérapeutiques chez des mammifères, notamment des humains. Les molécules de l'invention comprennent principalement trois segments ou domaines fonctionnels : un segment de ciblage, capable de se lier préférentiellement à la surface des cellules ciblées, un segment thérapeutique, comprenant le composé biologiquement actif, et un segment de liaison entre le segment de ciblage et le segment thérapeutique, le segment de liaison étant clivable sur le site cible. L'invention concerne également la préparation de ces molécules, des intermédiaires de synthèse ou domaines de celles-ci, des compositions pharmaceutiques les contenant, et leurs utilisation, en particulier dans le domaine pharmaceutique. Les molécules et compositions de l'invention sont tout particulièrement adaptées au ciblage de cellules pathologiques engagées dans une voie apoptotique, et au traitement de pathologies ou tissus associés, notamment les cancers et l'inflammation.
PCT/FR2004/001435 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation WO2004111090A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04767301A EP1631592A2 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
US10/560,025 US20060154854A1 (en) 2003-06-10 2004-06-09 Molecules for targeting and releasing therapeutic compounds, and the use thereof
CA002528186A CA2528186A1 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0306944A FR2856069A1 (fr) 2003-06-10 2003-06-10 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
FR03/06944 2003-06-10

Publications (2)

Publication Number Publication Date
WO2004111090A2 WO2004111090A2 (fr) 2004-12-23
WO2004111090A3 true WO2004111090A3 (fr) 2005-09-09

Family

ID=33484306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/001435 WO2004111090A2 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation

Country Status (5)

Country Link
US (1) US20060154854A1 (fr)
EP (1) EP1631592A2 (fr)
CA (1) CA2528186A1 (fr)
FR (1) FR2856069A1 (fr)
WO (1) WO2004111090A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
WO2013063086A1 (fr) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions et méthodes de traitement de protéinopathies
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US20190134231A1 (en) * 2016-04-21 2019-05-09 The Board Of Regents Of The University Of Texas System Methods and compositions for detecting aneurysms
WO2023161323A1 (fr) * 2022-02-23 2023-08-31 Resother Pharma A/S Analogues polypeptidiques dérivés de l'annexine a1

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009953A1 (fr) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Procedes permettant d'obtenir des proteines hybrides de fixation de phospholipides
WO1992019279A1 (fr) * 1991-05-09 1992-11-12 Board Of Regents Of The University Of Washington Agents thrombolytiques cibles sur des phospholipides
WO1999019470A2 (fr) * 1997-10-09 1999-04-22 The Regents Of The University Of California Proteines de fusion de la gfp et de l'annexine
WO1999060135A1 (fr) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation de produits geniques multiples a partir de proteines chimeres de fusion, par clivage a l'aide d'endoproteases ubiquistes
FR2784106A1 (fr) * 1998-10-02 2000-04-07 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
WO2003008594A1 (fr) * 2001-07-20 2003-01-30 Gene-Life Biotechnology (Shanghai) Limited Construction du plasmide pour l'expression de la proteine de fusion thrombolytique ciblant de thrombus
US20030059432A1 (en) * 2000-02-11 2003-03-27 Dillon Davin C. Lipophilin complexes for use in cancer diagnosis and therapy
WO2004003016A2 (fr) * 2002-07-01 2004-01-08 Commissariat A L'energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009953A1 (fr) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Procedes permettant d'obtenir des proteines hybrides de fixation de phospholipides
WO1992019279A1 (fr) * 1991-05-09 1992-11-12 Board Of Regents Of The University Of Washington Agents thrombolytiques cibles sur des phospholipides
WO1999019470A2 (fr) * 1997-10-09 1999-04-22 The Regents Of The University Of California Proteines de fusion de la gfp et de l'annexine
WO1999060135A1 (fr) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation de produits geniques multiples a partir de proteines chimeres de fusion, par clivage a l'aide d'endoproteases ubiquistes
FR2784106A1 (fr) * 1998-10-02 2000-04-07 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US20030059432A1 (en) * 2000-02-11 2003-03-27 Dillon Davin C. Lipophilin complexes for use in cancer diagnosis and therapy
WO2003008594A1 (fr) * 2001-07-20 2003-01-30 Gene-Life Biotechnology (Shanghai) Limited Construction du plasmide pour l'expression de la proteine de fusion thrombolytique ciblant de thrombus
WO2004003016A2 (fr) * 2002-07-01 2004-01-08 Commissariat A L'energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 1 October 1996 (1996-10-01), XP002269417, Database accession no. P09525 *

Also Published As

Publication number Publication date
US20060154854A1 (en) 2006-07-13
FR2856069A1 (fr) 2004-12-17
CA2528186A1 (fr) 2004-12-23
WO2004111090A2 (fr) 2004-12-23
EP1631592A2 (fr) 2006-03-08

Similar Documents

Publication Publication Date Title
WO2007127474A3 (fr) Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
EP2535355A3 (fr) Anticorps diriges contre CD38 pour le traitement du myelome multiple
EP4279140A3 (fr) Anticorps humains du facteur tissulaire
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases
WO2008063291A3 (fr) Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
ATE330967T1 (de) An her2 bindende peptidverbindungen
CL2007002169A1 (es) Compuestos derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso del compuesto para prevenir o tratar la inflamacion, trastornos urologicos, gastrointestina
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2007093183A3 (fr) Procede de traitement de maladies inflammatoires
WO2008130320A3 (fr) Nouveaux composés 806
WO2007038209A3 (fr) Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques
WO2005120461A3 (fr) Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
WO2006059234A3 (fr) Amides bicycliques comme inhibiteurs de kinases
WO2007120729A3 (fr) Composés de pyridylamide antagonistes des canaux calciques de type t
WO2008085794A3 (fr) Méthodes et compositions associées à des composés adhérant aux caillots
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2007064932A3 (fr) Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
NZ606480A (en) Albumin binding peptide-mediated disease targeting
WO2006055725A3 (fr) Acides amino carboxyliques substitues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004767301

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2528186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006516277

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006154854

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10560025

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004767301

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10560025

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004767301

Country of ref document: EP